InvestorsHub Logo

chickpea598

10/20/17 5:33 PM

#40466 RE: hschlauch #40465

Even if it is priced at half that, Oncosec will make a hell of a lot of money. Orphan drug designation comes with economic incentive too. $150,000 per patient in all reality is probably too high but would be nice.